argenex SE $ARGX Stock Holdings Raised by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC raised its stake in argenex SE (NASDAQ:ARGX) by 2.6% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 1,171 shares of the company’s stock after purchasing an additional 30 shares during the period. Janney Montgomery Scott LLC’s holdings in argenex were worth $645,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Rakuten Securities Inc. grew its position in shares of argenex by 56.4% during the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company’s stock valued at $36,000 after buying an additional 22 shares during the last quarter. WPG Advisers LLC bought a new stake in shares of argenex during the 1st quarter valued at about $37,000. Golden State Wealth Management LLC bought a new stake in shares of argenex during the 1st quarter valued at about $44,000. Brooklyn Investment Group grew its position in shares of argenex by 102.7% during the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock valued at $44,000 after buying an additional 38 shares during the last quarter. Finally, Banque Transatlantique SA bought a new stake in shares of argenex during the 1st quarter valued at about $62,000. Institutional investors own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

ARGX has been the subject of a number of recent research reports. Morgan Stanley boosted their price objective on shares of argenex from $766.00 to $1,040.00 and gave the company an “overweight” rating in a research report on Wednesday, October 1st. Deutsche Bank Aktiengesellschaft lowered shares of argenex from a “buy” rating to a “hold” rating in a research note on Thursday, September 11th. Zacks Research raised shares of argenex from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 22nd. Stifel Nicolaus set a $882.00 target price on shares of argenex in a research note on Thursday, September 18th. Finally, Royal Bank Of Canada began coverage on shares of argenex in a research note on Monday, August 25th. They set an “outperform” rating and a $850.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $817.53.

argenex Trading Up 2.7%

Shares of NASDAQ:ARGX opened at $837.28 on Friday. The company has a 50 day moving average of $731.05 and a 200-day moving average of $633.71. The firm has a market cap of $51.24 billion, a P/E ratio of 42.94, a P/E/G ratio of 0.88 and a beta of 0.46. argenex SE has a twelve month low of $510.05 and a twelve month high of $838.07.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.90. The company had revenue of $866.79 million during the quarter, compared to analyst estimates of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%. Equities research analysts forecast that argenex SE will post 3.13 EPS for the current year.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.